138 related articles for article (PubMed ID: 15627892)
1. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions.
Trapé J; Molina R; Sant F
Tumour Biol; 2004; 25(5-6):276-81. PubMed ID: 15627892
[TBL] [Abstract][Full Text] [Related]
2. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
3. Pleural CEA, CA-15-3, CYFRA 21-1, CA-19-9, CA-125 discriminating malignant from benign pleural effusions: Diagnostic cancer biomarkers.
Fazli Khalaf F; Asadi Gharabaghi M; Balibegloo M; Davari H; Afshar S; Jahanbin B
Int J Biol Markers; 2023 Jun; 38(2):81-88. PubMed ID: 36942429
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions.
Ferrer J; Villarino MA; Encabo G; Felip E; Bermejo B; Vilà S; Orriols R
Cancer; 1999 Oct; 86(8):1488-95. PubMed ID: 10526277
[TBL] [Abstract][Full Text] [Related]
5. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions.
Romero S; Fernández C; Arriero JM; Espasa A; Candela A; Martín C; Sánchez-Payá J
Eur Respir J; 1996 Jan; 9(1):17-23. PubMed ID: 8834328
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions.
Alataş F; Alataş O; Metintaş M; Colak O; Harmanci E; Demir S
Lung Cancer; 2001 Jan; 31(1):9-16. PubMed ID: 11162861
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions.
Salama G; Miédougé M; Rouzaud P; Mauduyt MA; Pujazon MC; Vincent C; Carles P; Serre G
Br J Cancer; 1998; 77(3):472-6. PubMed ID: 9472646
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions.
Korczynski P; Krenke R; Safianowska A; Gorska K; Abou Chaz MB; Maskey-Warzechowska M; Kondracka A; Nasilowski J; Chazan R
Eur J Med Res; 2009 Dec; 14 Suppl 4(Suppl 4):128-33. PubMed ID: 20156743
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.
Lee JH; Chang JH
Chest; 2005 Oct; 128(4):2298-303. PubMed ID: 16236887
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature.
Shitrit D; Zingerman B; Shitrit AB; Shlomi D; Kramer MR
Oncologist; 2005 Aug; 10(7):501-7. PubMed ID: 16079317
[TBL] [Abstract][Full Text] [Related]
11. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
Klech H; Rona G; Hutter C; Bayer PM; Kummer F
Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis.
Nguyen AH; Miller EJ; Wichman CS; Berim IG; Agrawal DK
Transl Res; 2015 Nov; 166(5):432-9. PubMed ID: 25953662
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic significance of the tumour markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer.
Kandylis K; Vassilomanolakis M; Baziotis N; Papadimitriou A; Tsoussis S; Ferderigou A; Efremidis AP
Ann Oncol; 1990 Nov; 1(6):435-8. PubMed ID: 2083187
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
Gaspar MJ; De Miguel J; García Díaz JD; Díez M
Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of tumoural markers in pleural effusions.
Ustün H; Borazan A; Bilgiçli N; Yilmaz A
Int J Clin Pract; 2004 Jan; 58(1):22-5. PubMed ID: 14994966
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of serum and pleural levels of the tumor markers CEA, CYFRA21-1 and CA 15-3 in patients with pleural effusion.
Wagner IC; Guimarães MJ; da Silva LK; de Melo FM; Muniz MT
J Bras Pneumol; 2007; 33(2):185-91. PubMed ID: 17724538
[TBL] [Abstract][Full Text] [Related]
17. Tumour associated antigens in diagnosis of serous effusions.
Mezger J; Permanetter W; Gerbes AL; Wilmanns W; Lamerz R
J Clin Pathol; 1988 Jun; 41(6):633-43. PubMed ID: 2454957
[TBL] [Abstract][Full Text] [Related]
18. CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers.
Ferroni P; Szpak C; Greiner JW; Simpson JF; Guadagni F; Johnston WW; Colcher D
Int J Cancer; 1990 Sep; 46(3):445-51. PubMed ID: 2394511
[TBL] [Abstract][Full Text] [Related]
19. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions.
Lee YC; Knox BS; Garrett JE
Aust N Z J Med; 1999 Dec; 29(6):765-9. PubMed ID: 10677119
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin.
Kuralay F; Tokgöz Z; Cömlekci A
Clin Chim Acta; 2000 Oct; 300(1-2):43-55. PubMed ID: 10958862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
